Kubulus Darius, Mathes Alexander, Reus Erik, Pradarutti Sascha, Pavlidis Daphne, Thierbach Jan-Tobias, Heiser Jochen, Wolf Beate, Bauer Inge, Rensing Hauke
Department of Anesthesiology and Critical Care Medicine, University of the Saarland, Homburg, Germany.
Shock. 2009 Aug;32(2):179-89. doi: 10.1097/SHK.0b013e318199352b.
Hemoglobin glutamer-200 (HbG) might be an alternative to human blood. However, artificial oxygen carriers are initially successful to restore oxygen supply but may induce organ dysfunction and increase mortality several days after application in terms of delayed side effects. Impairment of microcirculation and an inflammatory cytokine response through induction of endothelin (ET) 1 may contribute. We investigated the role of HbG for the therapy of hemorrhagic shock and for delayed side effects in a model of hemorrhagic shock and reperfusion (H/R). To analyze early effects, Sprague-Dawley rats (n = 8/group) were resuscitated after hemorrhagic shock (1 h) with shed blood or HbG followed by reperfusion (2 h). Hemorrhagic shock and reperfusion decreased liver microcirculation and hepatic function in both shock groups to the same extent. Thus, HbG was not superior to shed blood regarding resuscitation end points after hemorrhagic shock. To determine delayed effects, rats (n = 8/group) were pretreated with Ringer's solution (vehicle) or HbG (1 g/kg) 24 h before H/R. Endothelin receptors were blocked with bosentan. Subsequently, ET-1 expression, inflammatory response, sinusoidal perfusion, hepatocellular function (plasma disappearance rate of indocyanine green [PDRICG]), and redox state [NAD(P)H] were analyzed. After vehicle pretreatment, H/R increased ET-1, hepatocellular injury, NAD(P)H, and cytokine levels. Sinusoidal perfusion and PDRICG decreased. After HbG pretreatment, a further increase of ET-1 and hepatocellular injury was observed, whereas PDRICG further decreased. Application of bosentan after HbG but not after vehicle pretreatment significantly improved PDRICG and liver perfusion, whereas NAD(P)H and hepatocellular injury decreased. Furthermore, cytokine release changed to an anti-inflammatory response. These data suggest an HbG-dependent increase of ET-1, which may contribute to delayed side effects under shock conditions.
血红蛋白谷氨酰胺-200(HbG)可能是人类血液的一种替代品。然而,人工氧载体最初能成功恢复氧气供应,但在应用几天后可能会因延迟的副作用而导致器官功能障碍并增加死亡率。通过诱导内皮素(ET)1导致的微循环损伤和炎症细胞因子反应可能是其原因。我们在失血性休克和再灌注(H/R)模型中研究了HbG在失血性休克治疗及延迟副作用方面的作用。为分析早期效应,将Sprague-Dawley大鼠(每组n = 8)在失血性休克(1小时)后用自体失血或HbG进行复苏,随后再灌注(2小时)。在两个休克组中,失血性休克和再灌注均使肝脏微循环和肝功能下降到相同程度。因此,在失血性休克后的复苏终点方面,HbG并不优于自体失血。为确定延迟效应,在H/R前24小时,将大鼠(每组n = 8)用林格氏液(赋形剂)或HbG(1 g/kg)进行预处理。用波生坦阻断内皮素受体。随后,分析ET-1表达、炎症反应、肝血窦灌注、肝细胞功能(吲哚菁绿血浆消失率[PDRICG])和氧化还原状态[NAD(P)H]。在用赋形剂预处理后,H/R增加了ET-1、肝细胞损伤、NAD(P)H和细胞因子水平。肝血窦灌注和PDRICG下降。在用HbG预处理后,观察到ET-1和肝细胞损伤进一步增加,而PDRICG进一步下降。在HbG预处理后而非赋形剂预处理后应用波生坦可显著改善PDRICG和肝脏灌注,而NAD(P)H和肝细胞损伤减少。此外,细胞因子释放转变为抗炎反应。这些数据表明ET-1的增加依赖于HbG,这可能导致休克条件下的延迟副作用。